Skip to main content
Philogen logo

Philogen — Investor Relations & Filings

Ticker · PHIL ISIN · IT0005373789 LEI · 81560009EA1577917768 XMIL Manufacturing
Open in API
Filings indexed 375 across all filing types
Latest filing 2026-05-12 Earnings Release
Country IT Italy
Listing XMIL PHIL

About Philogen

https://www.philogen.com

Philogen is a clinical-stage biotechnology company focused on the discovery and development of novel biopharmaceutical products for the treatment of cancer and other serious conditions associated with angiogenesis. Founded in 1996, the company's core strategy is based on innovating targeted therapies, such as antibody-cytokine fusions, which are designed to selectively deliver therapeutic agents to the site of disease. This approach aims to increase efficacy while reducing toxicity. Philogen operates as an integrated company with capabilities in research, GMP manufacturing, and clinical development of its proprietary product pipeline.

Recent filings

Filing Released Lang Actions
The Board of Directors approves the financial position for the first quarter of 2026
Earnings Release Classification · 85% confidence The document is a press release summarizing the first quarter 2026 results (net financial position) and business updates, including narrative commentary by the CEO and pipeline progress, together with a share buyback launch. It is not the full interim report (no complete financial statements), but an initial earnings announcement – key highlights only – fitting the Earnings Release definition. Q1 2026
2026-05-12 English
Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa al Primo Trimestre 2026
Earnings Release Classification · 85% confidence The document is a corporate press release (“COMUNICATO STAMPA”) announcing Phylogen’s first‐quarter net financial position, key clinical pipeline updates and the launch of a share buy‐back program. It contains substantive financial data for Q1 2026 (net debt table), narrative management commentary on performance and future plans, and it serves as the initial public announcement of interim results. This aligns with the definition of an Earnings Release (ER), which is used for initial quarterly or periodic financial results announcements. Q1 2026
2026-05-12 Italian
Allegato 3F
Regulatory Filings
2026-05-04 Italian
L'Assemblea degli Azionisti di Philogen S.p.A. ha approvato il bilancio 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 94% confidence The document is a press release summarizing Phylogen S.p.A.’s 2026 Annual General Meeting resolutions: approval of the 2025 financial statements, dividend distribution, remuneration policy votes, and share buyback authorization. It provides the voting turnout (77.141% of capital, 85.345% of votes) and details all resolutions approved by shareholder vote. This matches “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-04-29 Italian
2026 27 04 - CS settimanale acquisto azioni proprie
Transaction in Own Shares Classification · 95% confidence The document is a press release (COMUNICATO STAMPA) providing detailed daily and aggregate statistics of Philogen’s own share repurchase program (number of shares bought, dates, prices, total values). This matches the definition of a Transaction in Own Shares (share buyback) announcement, corresponding to code POS.
2026-04-27 Italian
2026 20 04 - CS settimanale acquisto azioni proprie
Transaction in Own Shares Classification · 91% confidence The document is a press release (“COMUNICATO STAMPA”) providing a detailed update on Philogen S.p.A.’s share repurchase programme, including quantities, dates, prices and regulatory compliance details under EU Delegated Regulation. This clearly matches a company’s transaction in its own shares (share buyback). Therefore, the correct classification is POS (Transaction in Own Shares).
2026-04-20 Italian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.